MENU
+Compare
COLL
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$29.13
Change
-$0.62 (-2.08%)
Capitalization
1.24B

COLL stock forecast, quote, news & analysis

COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for COLL with price predictions
Feb 18, 2025

COLL's Stochastic Oscillator is remaining in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where COLL advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

COLL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on COLL as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for COLL turned negative on January 30, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

COLL moved below its 50-day moving average on February 12, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for COLL crossed bearishly below the 50-day moving average on February 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where COLL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.365) is normal, around the industry mean (59.679). P/E Ratio (30.171) is within average values for comparable stocks, (89.540). COLL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.913). Dividend Yield (0.000) settles around the average of (0.120) among similar stocks. P/S Ratio (2.869) is also within normal values, averaging (19.827).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. COLL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 3.6B. The market cap for tickers in the group ranges from 246 to 77.48B. ZTS holds the highest valuation in this group at 77.48B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -1%. For the same Industry, the average monthly price growth was 78%, and the average quarterly price growth was 51%. ECGS experienced the highest price growth at 154%, while INNPF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 65%. For the same stocks of the Industry, the average monthly volume growth was 82% and the average quarterly volume growth was 249%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 69
Price Growth Rating: 62
SMR Rating: 84
Profit Risk Rating: 90
Seasonality Score: -41 (-100 ... +100)
View a ticker or compare two or three
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
100 Technology Center Drive
Phone
+1 781 713-3699
Employees
197
Web
https://www.collegiumpharma.com